Early prediction and prevention of venous thromboembolism is crucial in high-risk populations, such as hospitalized patients with bladder cancer.
Oct. 7, 2005 — The U.S. Food and Drug Administration (FDA) has approved an assay for the detection of epidermal growth factor receptor mutations in patients with non-small cell lung cancer; a D-dimer ...
Paul Brunetta, M.D., joins as Chief Medical Officer; Kristen Quigley joins as Chief Clinical Operations Officer; Alpana Naresh, Ph.D., joins as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback